SCHLIEREN, Switzerland, February 22, 2024 LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S
Leveraging data from 1715 children in the MAL-ED birth cohort study, Stephanie A Brennhofer and colleagues model the expected reduction in diarrhea episodes, antibiotic use, and bystander pathogen exposure to antibiotics through the administration of Shigella vaccines.